2022
Factors Associated With Palliative Intervention Utilization for Metastatic Renal Cell Carcinoma
Patel HV, Kim S, Srivastava A, Shinder BM, Sterling J, Saraiya B, Mayer TM, Ghodoussipour S, Jang TL, Singer EA. Factors Associated With Palliative Intervention Utilization for Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer 2022, 20: 296-296.e9. PMID: 35105510, PMCID: PMC9149103, DOI: 10.1016/j.clgc.2022.01.001.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, Renal CellCohort StudiesHumansKidney NeoplasmsNeoplasm StagingQuality of LifeConceptsStage IV RCCMetastatic renal cell carcinomaNational Cancer DatabasePalliative interventionsRenal cell carcinomaMetastatic RCCClinical factorsCell carcinomaMultivariable logistic regression modelComprehensive cancer programsQuality of lifeLogistic regression modelsSarcomatoid histologyAdvanced malignanciesOverall cohortHigher education statusOncologic careInsurance statusCancer DatabaseCancer programsEarly initiationIntervention utilizationTreatment-specific mannerPatientsPI use
2020
Delaying surgery for clinical T1b-T2bN0M0 renal cell carcinoma: Oncologic implications in the COVID-19 era and beyond
Srivastava A, Patel HV, Kim S, Shinder B, Sterling J, Tabakin AL, Polotti CF, Saraiya B, Mayer T, Kim IY, Ghodoussipour S, Patel HD, Jang TL, Singer EA. Delaying surgery for clinical T1b-T2bN0M0 renal cell carcinoma: Oncologic implications in the COVID-19 era and beyond. Urologic Oncology Seminars And Original Investigations 2020, 39: 247-257. PMID: 33223368, PMCID: PMC7574787, DOI: 10.1016/j.urolonc.2020.10.012.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaUpstaging riskOverall survivalCell carcinomaNonclear cell renal cell carcinomaOrgan-confined renal cell carcinomaCox proportional hazards modelNational Cancer DatabaseCell renal cell carcinomaKaplan-Meier curvesProportional hazards modelSmall renal massesCOVID-19Logistic regression modelsPT3a upstagingDelaying surgeryPrimary endpointSecondary endpointsPatient comorbiditiesMeier curvesElective surgeryRadical nephrectomyTumor histologyClinical stageRCC patients
2019
Retroperitoneal Lymph Node Dissection as Primary Treatment for Men With Testicular Seminoma: Utilization and Survival Analysis Using the National Cancer Data Base, 2004-2014
Tabakin AL, Shinder BM, Kim S, Rivera-Nunez Z, Polotti CF, Modi PK, Sterling JA, Farber NJ, Radadia KD, Parikh RR, Kim IY, Saraiya B, Mayer TM, Singer EA, Jang TL. Retroperitoneal Lymph Node Dissection as Primary Treatment for Men With Testicular Seminoma: Utilization and Survival Analysis Using the National Cancer Data Base, 2004-2014. Clinical Genitourinary Cancer 2019, 18: e194-e201. PMID: 31818649, DOI: 10.1016/j.clgc.2019.10.018.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultFollow-Up StudiesHumansKaplan-Meier EstimateLymph Node ExcisionLymph NodesLymphatic MetastasisMaleMiddle AgedNeoplasm StagingOrchiectomyRegistriesRetroperitoneal SpaceRetrospective StudiesSeminomaSurvival RateTesticular NeoplasmsTestisTreatment OutcomeUnited StatesYoung AdultConceptsRetroperitoneal lymph node dissectionPrimary retroperitoneal lymph node dissectionLymph node dissectionOverall survivalTesticular seminomaNode dissectionRole of RPLNDTesticular nonseminomatous germ cell tumorsNational Cancer Data BaseNonseminomatous germ cell tumorsPrimary testicular cancerFive-year OSFirst-line treatmentKaplan-Meier methodOngoing prospective trialsGerm cell tumorsIIB diseaseOS ratesPrimary chemotherapyPrimary therapyProspective trialFinal cohortStage IIATumor histologyClinical stage